Boston Scientific (NYSE: [[ticker:BSX]]) disclosed in an annual report filed today with the SEC that the Department of Justice is conducting a civil investigation of allegations that the Natick, MA firm and other manufacturers promoted off-label uses of biliary stents. The company indicated it plants to cooperate with the investigation, though none of its documents have been subpoenaed.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
